Current and Emerging Immunotherapeutic Approaches to the Treatment of Multiple Myeloma

Overview

Journal Ther Adv Hematol

Specialty Hematology

Date 2019 Jun 28

PMID 31244984

Citations 10

Authors

Dawn Swan

Kevin Lynch

Mark Gurney

Michael ODwyer

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma (MM) has a worldwide incidence of 1-5/100,000/year. Outcomes have improved significantly in recent years following incorporation of immunomodulatory drugs and proteasome inhibitors into standard-of-care regimes. MM is profoundly immunosuppressive, enabling immune evasion, proliferation and disease progression. The role of the immune system in MM is becoming increasingly characterized and understood, and numerous therapies are under development or in routine clinical use targeting these elements of MM pathogenesis. In this review we discuss the immunosuppressive effects of MM, then the therapies targeting these defects. Specifically, we review the monoclonal and bispecific antibodies, alongside adoptive cellular therapies currently under investigation.

Citing Articles

Antibody avidity meets multiple myeloma.

Ruuls S, Parren P Nat Cancer. 2024; 5(10):1452-1454.

PMID: 39261677 DOI: 10.1038/s43018-024-00805-1.

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.

Zhou M, Chen Y, Gong Y, Zhu M, Cen J, Pan J Discov Oncol. 2024; 15(1):78.

PMID: 38502423 PMC: 10951185. DOI: 10.1007/s12672-024-00938-w.

Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor.

Gordan L, Ray D, Ijioma S, Dranitsaris G, Warner A, Heritage T Curr Oncol. 2024; 31(1):501-510.

PMID: 38248119 PMC: 10814155. DOI: 10.3390/curroncol31010034.

Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.

Avivi I, Vesole D, Davila-Valls J, Usnarska-Zubkiewicz L, Olszewska-Szopa M, Milunovic V Cancers (Basel). 2023; 15(17).

PMID: 37686635 PMC: 10487060. DOI: 10.3390/cancers15174359.

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.

Swamydas M, Murphy E, Ignatz-Hoover J, Malek E, Driscoll J J Hematol Oncol. 2022; 15(1):17.

PMID: 35172851 PMC: 8848665. DOI: 10.1186/s13045-022-01234-2.

References

Brown R, Pope B, Yuen E, Gibson J, Joshua D . The expression of T cell related costimulatory molecules in multiple myeloma. Leuk Lymphoma. 1998; 31(3-4):379-84. DOI: 10.3109/10428199809059231. View

Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W . Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006; 203(12):2691-702. PMC: 2118163. DOI: 10.1084/jem.20061104. View

Rapoport A, Stadtmauer E, Binder-Scholl G, Goloubeva O, Vogl D, Lacey S . NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015; 21(8):914-921. PMC: 4529359. DOI: 10.1038/nm.3910. View

Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E . Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood. 2008; 112(3):750-9. PMC: 5070715. DOI: 10.1182/blood-2008-02-139378. View

Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L . Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. Front Immunol. 2017; 8:1444. PMC: 5682004. DOI: 10.3389/fimmu.2017.01444. View

Hipp S, Tai Y, Blanset D, Deegen P, Wahl J, Thomas O . A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017; 31(10):2278. DOI: 10.1038/leu.2017.219. View

Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman G, Borrello I . A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood. 2010; 116(18):3554-63. PMC: 4017298. DOI: 10.1182/blood-2010-05-283895. View

Reddy N, Hernandez-Ilizaliturri F, Deeb G, Roth M, Vaughn M, Knight J . Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2007; 140(1):36-45. DOI: 10.1111/j.1365-2141.2007.06841.x. View

Noonan K, Huff C, Davis J, Lemas M, Fiorino S, Bitzan J . Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015; 7(288):288ra78. PMC: 4634889. DOI: 10.1126/scitranslmed.aaa7014. View

10.

Song W, van der Vliet H, Tai Y, Prabhala R, Wang R, Podar K . Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 2008; 14(21):6955-62. PMC: 2967459. DOI: 10.1158/1078-0432.CCR-07-5290. View

11.

Dimopoulos M, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J . Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017; 178(6):896-905. PMC: 6084289. DOI: 10.1111/bjh.14787. View

12.

Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L . Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009; 114(13):2667-77. PMC: 2756126. DOI: 10.1182/blood-2009-02-206532. View

13.

Frohn C, Hoppner M, Schlenke P, Kirchner H, Koritke P, Luhm J . Anti-myeloma activity of natural killer lymphocytes. Br J Haematol. 2002; 119(3):660-4. DOI: 10.1046/j.1365-2141.2002.03879.x. View

14.

Kumar S, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F . Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2007; 111(5):2516-20. PMC: 2254544. DOI: 10.1182/blood-2007-10-116129. View

15.

Ghosh N, Matsui W . Cancer stem cells in multiple myeloma. Cancer Lett. 2008; 277(1):1-7. PMC: 2657813. DOI: 10.1016/j.canlet.2008.08.005. View

16.

Dosani T, Carlsten M, Maric I, Landgren O . The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 2015; 5:e321. PMC: 4526775. DOI: 10.1038/bcj.2015.49. View

17.

Liegel J, Avigan D, Rosenblatt J . Cellular immunotherapy as a therapeutic approach in multiple myeloma. Expert Rev Hematol. 2018; 11(7):525-536. DOI: 10.1080/17474086.2018.1483718. View

18.

El-Sherbiny Y, Meade J, Holmes T, McGonagle D, Mackie S, Morgan A . The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007; 67(18):8444-9. DOI: 10.1158/0008-5472.CAN-06-4230. View

19.

Mikkilineni L, Kochenderfer J . Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017; 130(24):2594-2602. PMC: 5731088. DOI: 10.1182/blood-2017-06-793869. View

20.

Groh V, Wu J, Yee C, Spies T . Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002; 419(6908):734-8. DOI: 10.1038/nature01112. View